Edgewise Therapeutics (EWTX) Net Income towards Common Stockholders (2020 - 2026)

Edgewise Therapeutics has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$49.0 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$49.0 million, down 20.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$176.0 million (down 20.48% YoY), and the FY2025 annual result was -$167.8 million, down 25.4% from the prior year.
• Net Income towards Common Stockholders came in at -$49.0 million for Q1 2026 at Edgewise Therapeutics, up from -$50.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$14.7 million in Q1 2022 to a low of -$50.2 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$30.1 million (2023), against an average of -$30.5 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 115.11% in 2022 and dropped 14.66% in 2025, its largest moves.
• Edgewise Therapeutics' Net Income towards Common Stockholders stood at -$19.4 million in 2022, then sank by 55.26% to -$30.1 million in 2023, then plunged by 31.58% to -$39.7 million in 2024, then declined by 26.61% to -$50.2 million in 2025, then grew by 2.4% to -$49.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$49.0 million (Q1 2026), -$50.2 million (Q4 2025), and -$40.7 million (Q3 2025), per Business Quant data.